Gyre Therapeutics, Inc. Net Change in Cash
Gyre Therapeutics, Inc. (GYRE) reported Net Change in Cash of -$5.91 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-07
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $431.00K, a 86.66% decline year-over-year.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $3.23M.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$3.72M, a 225.43% decline year-over-year.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was $2.97M.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $25.26M.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$21.70M, a 360.33% decline from fiscal 2023.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was $8.33M.
- Gyre Therapeutics, Inc. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$5.03M, a 135.95% decline from fiscal 2021.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.91M 10-Q · filed 2026-08-07 | |||||||
| 2026-03-31 | $431.00K 10-Q · filed 2026-05-08 | |||||||
| 2025-12-31 | $25.26M 10-K · filed 2026-03-13 | |||||||
| 2025-09-30 | $28.59M 10-Q · filed 2025-11-07 | |||||||
| 2025-06-30 | $17.32M 10-Q · filed 2026-08-07 | $24.68M 10-Q · filed 2025-08-11 | ||||||
| 2025-03-31 | $3.23M 10-Q · filed 2026-05-08 | |||||||
| 2024-12-31 | -$21.70M 10-K · filed 2026-03-13 | |||||||
| 2024-09-30 | -$17.64M 10-Q · filed 2025-11-07 | |||||||
| 2024-06-30 | -$17.41M 10-Q · filed 2025-08-11 | |||||||
| 2024-03-31 | -$3.72M 10-Q · filed 2025-05-09 | |||||||
| 2023-12-31 | $8.33M 10-K · filed 2025-03-17 | |||||||
| 2023-09-30 | $904.00K 10-Q · filed 2024-11-13 | -$19.44M 10-Q · filed 2023-10-26 | ||||||
| 2023-06-30 | -$1.45M 10-Q · filed 2024-08-13 | -$14.74M 10-Q · filed 2023-08-14 | ||||||
| 2023-03-31 | $2.97M 10-Q · filed 2024-05-13 | -$13.57M 10-Q · filed 2023-05-15 | ||||||
| 2022-12-31 | -$5.03M 10-K · filed 2024-03-27 | -$22.68M 10-K · filed 2023-03-30 | ||||||
| 2022-09-30 | -$21.26M 10-Q · filed 2023-10-26 | |||||||
| 2022-06-30 | $31.05M 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | -$9.53M 10-Q · filed 2023-05-15 | |||||||
| 2021-12-31 | $13.99M 10-K · filed 2023-03-30 | |||||||
| 2021-09-30 | $28.80M 10-Q · filed 2022-11-14 | |||||||
| 2021-06-30 | $43.26M 10-Q · filed 2022-08-15 | |||||||
| 2021-03-31 | $52.68M 10-Q · filed 2022-05-09 | |||||||
| 2020-12-31 | $14.99M 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | $9.55M 10-Q · filed 2021-11-12 | |||||||
| 2020-06-30 | $43.90M 10-Q · filed 2021-08-05 | |||||||
| 2020-03-31 | $54.99M 10-Q · filed 2021-05-06 | |||||||
| 2019-12-31 | -$15.89M 10-K · filed 2021-03-04 | |||||||
| 2019-09-30 | -$8.24M 10-Q · filed 2020-11-05 | |||||||
| 2019-06-30 | -$13.87M 10-Q · filed 2020-08-06 | |||||||
| 2019-03-31 | -$6.19M 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $11.46M 10-K · filed 2020-02-20 | |||||||
| 2018-09-30 | $16.24M 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | $26.90M 10-Q · filed 2019-08-01 | |||||||
| 2018-03-31 | $106.92M 10-Q · filed 2019-05-02 | |||||||
| 2017-12-31 | -$10.05M 10-K · filed 2019-03-08 | |||||||
| 2017-09-30 | -$13.16M 10-Q · filed 2018-11-01 | |||||||
| 2017-06-30 | $8.53M 10-Q · filed 2018-08-02 | |||||||
| 2017-03-31 | -$2.46M 10-Q · filed 2018-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |